The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of concurrent cetuximab (C225) versus 5-fluorouracil/carboplatin (5FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC).
Lauren Quinn Shapiro
No relevant relationships to disclose
Eric Jeffrey Sherman
Consultant or Advisory Role - Bristol-Myers Squibb
Lawrence Koutcher
No relevant relationships to disclose
Jeremy Setton
No relevant relationships to disclose
Zhigang Zhang
No relevant relationships to disclose
Weiji Shi
No relevant relationships to disclose
Shyam S. Rao
No relevant relationships to disclose
Matthew G. Fury
Research Funding - Bristol-Myers Squibb
Suzanne L. Wolden
No relevant relationships to disclose
Dennis Kraus
Honoraria - Ethicon
David G. Pfister
Research Funding - ImClone Systems
Nancy Y. Lee
No relevant relationships to disclose